» Articles » PMID: 7550367

Genetic Analysis of the CYP2D Locus in Relation to Debrisoquine Hydroxylation Capacity in Korean, Japanese and Chinese Subjects

Overview
Specialties Genetics
Pharmacology
Date 1995 Jun 1
PMID 7550367
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The CYP2D6 genotype and the debrisoquine and mephenytoin hydroxylation phenotypes were studied in 63 Oriental subjects including 21 Chinese, 21 Japanese and 21 Koreans. All subjects were extensive metabolizers of debrisoquine. The incidence of the S-mephenytoin poor metabolizer phenotype was 14% in the Chinese, 24% in the Japanese and 24% in the Korean population, respectively, which is similar to previous reports. The CYP2D6 genotype was analysed by Xba I and Eco RI RFLP, and by allele-specific PCR analysis for the presence of several allelic variants of the CYP2D locus. No CYP2D6A or CYP2D6B alleles, two of the most common defect alleles among Caucasians, were found among the Oriental subjects. The frequency of the CYP2D6D allele was similar to that in Caucasian populations and consistent with the low incidence of the poor metabolizer phenotype in all three Oriental populations. The CYP2D6L2-allele with duplication of an active CYP2D6L gene was identified in one Korean and one Chinese allele in association with high CYP2D6 activity. The CYP2D6Ch alleles CYP2D6Ch1 and Ch2, identified by RFLP and PCR for the -1338C-->T and 188C-->T mutations, were the most frequent allelic variants in all three populations studied, and were related to a decreased CYP2D6 activity as previously shown in Chinese. In conclusion, the present pilot study revealed major similarities in the polymorphic CYP2D locus between Korean, Japanese and Chinese populations.

Citing Articles

Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer.

Tan E, Bharwani L, Chia Y, Soong R, Lee S, Chen J World J Clin Oncol. 2022; 13(8):712-724.

PMID: 36160461 PMC: 9476606. DOI: 10.5306/wjco.v13.i8.712.


Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions.

Kilford P, Khoshaein N, Southall R, Gardner I Eur J Drug Metab Pharmacokinet. 2022; 47(5):699-710.

PMID: 35840839 DOI: 10.1007/s13318-022-00775-8.


Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression- an Asian Sub-group Analysis from the SUSTAIN-2 Study.

Jeon H, Ju P, Sulaiman A, Abdul Aziz S, Paik J, Tan W Clin Psychopharmacol Neurosci. 2022; 20(1):70-86.

PMID: 35078950 PMC: 8813327. DOI: 10.9758/cpn.2022.20.1.70.


P450 Pharmacogenetics in Indigenous North American Populations.

Henderson L, Claw K, Woodahl E, Robinson R, Boyer B, Burke W J Pers Med. 2018; 8(1).

PMID: 29389890 PMC: 5872083. DOI: 10.3390/jpm8010009.


Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.

Bagheri A, Kamalidehghan B, Haghshenas M, Azadfar P, Akbari L, Sangtarash M Drug Des Devel Ther. 2015; 9:2627-34.

PMID: 25999696 PMC: 4435087. DOI: 10.2147/DDDT.S79709.